Skip to main content

Table 1 Demographic, clinical and lung involvement characteristics of 46 scleroderma patients

From: β-thymosins and interstitial lung disease: study of a scleroderma cohort with a one-year follow-up

  All scleroderma Patients 24 scleroderma pts with alveolitis 22 scleroderma pts without alveolitis
Age (y, mean ± SD) 55.1 ± 14 60.6 ± 11.7* 49 ± 14
Disease duration (y, mean ± SD)** 6.1 ± 6.2 5.4 ± 5.4 6.9 ± 7.1
Early disease (<3 y) n (%) 21 (45.6%) 12 (50%) 9 (40.9%)
Female n (%) 36 (78.3%) 20 (83.3%) 16 (72.7%)
dSSc n (%) 15 (32.6%) 7 (29.2%) 8 (36.4%)
AntiScl70 n (%) 28 (60.9%) 16 (66.7%) 12 (54.5%)
Anticentromere n (%) 5 (10.9%) 2 (8.3%) 3 (12.6%)
Antiribonucleoprotein n (%) 3 (6.5%) 1 (4.2%) 2 (9.1%)
Antinucleolus n (%) 3 (6.5%) 2 (8.3%) 1 (4.5%)
FVC% (mean ± SD) 93.1 ± 20.9 89.2 ± 23.1 97.3 ± 17.8
DLCO% (mean ± SD) 52.3 ± 14.8 48.9 ± 17.1 56 ± 11.2
Restrictive lung disease n (%) 14 (30.4%) 11 (45.8%)* 3 (13.6%)
Ground glass score (mean ± SD) 7.8 ± 5.6 9.7 ± 5.8* 5.6 ± 4.6
Interstitial score (mean ± SD) 6.3 ± 2.7 6.6 ± 2.8 5.9 ± 2.6
Alveolitis on BALF 24 (52.2%) / /
PASP (mmHg; mean ± SD) 27.8 ± 5.7 30.8 ± 5.7* 25.1 ± 4.2
HPAP n (%) 5 (10.9%) 5 (20.8%)* 0
Treatment n (%) 12 (26.1%) 12 (50.0%) 0
Smokers n (%) 6 (13%) 4 (16.7%) 2 (9.1%)
  1. pts: patients; y: years; SD: standard deviation; n: number; dSSc: diffuse disease; FVC: forced vital capacity; DLCO: carbon monoxide diffusing capacity; BALF: bronchoalveolar lavage fluid; PASP: pulmonary arterial systolic pressure; HPAP: high pulmonary arterial pressure;
  2. *p < 0.05: pts with alveolitis versus pts without alveolitis
  3. ** first SSc sign other than Raynaud's phenomenon